APA aipamena

Bendell, J. C., Hochster, H., Hart, L. L., Firdaus, I., Mace, J. R., McFarlane, J. J., . . . Cohn, A. L. (2017). A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist.

Chicago Style aipamena

Bendell, Johanna C., et al. "A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab With or Without the MET Inhibitor Onartuzumab in Patients With Metastatic Colorectal Cancer." Oncologist 2017.

MLA aipamena

Bendell, Johanna C., et al. "A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab With or Without the MET Inhibitor Onartuzumab in Patients With Metastatic Colorectal Cancer." Oncologist 2017.